Improved estimates of COVID-19 correlates of protection, antibody decay and vaccine efficacy waning: a joint modelling approach
Phillips, D. J.; Christodoulou, M. D.; Feng, S.; Pollard, A. J.; Voysey, M.; Steinsaltz, D.
Show abstract
Reliable estimation of the relationship between COVID-19 antibody levels at the time of exposure and the risk of infection is crucial to inform policy decisions on vaccination regimes. We fit a joint model of anti-spike IgG antibody decay and risk of COVID-19 infection to data from a randomized efficacy trial of the ChAdOx1 nCoV-19 vaccine. Our model improves upon previous analyses by accounting for measurement error, decay in antibody levels and variation between different individuals. We estimated correlates of protection, antibody decay, and vaccine efficacy waning. Increased anti-spike IgG antibody levels at the time of exposure correlate with increased vaccine-induced protection. We estimated vaccine efficacy against symptomatic COVID-19 infection of 88.1% (95% CrI: 77.2, 93.6) at day 35, waning to 60.4% (44.6, 71.0) at day 189 since the second dose. We report that longer intervals between the first and second vaccine dose give lasting increased protection, and observe lower efficacy in individuals aged [≥]70 years from around 3 months after second dose. Our methods can be used in future vaccine trials to help inform the timings and priority of vaccine administration against novel diseases.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort 96%
- Effect of booster vaccination against Delta and Omicron variants in Iceland 96%
- Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial 95%
Similar papers in this journal
- Implementation and Adherence to Regular Asymptomatic Testing in a COVID-19 Vaccine Trial 96%
- COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study 95%
- Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19 95%
Similar papers in this journal
- BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure; Analysis of Household Members of COVID-19 Patients 95%
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 94%
- Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada 94%
Similar papers in this journal
- Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors 96%
- Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein after infection and/or vaccination 94%
- Assessing Healthy Vaccinee Bias in COVID-19 Vaccine Effectiveness Studies: A National Cohort Study in Qatar 93%
Similar papers in this journal
- Long term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: a modelling study 95%
- Health impact and cost-effectiveness of COVID-19 vaccination in Sindh Province, Pakistan 94%
- Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.